Evaluation of the Right Use of Inhaled Therapeutics

NCT03395418 | Completed

• 1 other identifier: 2017-A02599-44
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Asthma and COPD have a significant impact on public health, affecting about 8 million people in France and generating health care costs of 5.5 billion euros, almost 50% of which are dedicated to long-term treatments are essentially inhaled therapies. The good control of the disease depends on the patient's compliance, but also on the proper use of the devices used for the administration of inhaled drugs under penalty of the degradation of the control of the disease with major medical and medico-economic consequences. Thus, education of these patients in the use of devices must be an integral part of medical care. It comes up against the complexity of the therapeutic arsenal on the one hand and on the other hand with its time-consuming nature: this makes it incompatible with a realization in consultation. The "ARGOS" process is a telemonitoring project for the support of therapeutic education, consisting in setting up a concrete and real-time relay between prescribers and patients for the education of inhaled therapeutics. Its objective is to provide the answer to what is currently an "unmet need" in the management of asthma and COPD, with the prospect of a positive impact on the observance of these treatments and by consequently their clinical and economic efficiency.

Conditions

COPD Asthma

Keywords

COPD; Asthma; Inhaled Therapeutics

Outcome Measures

Primary Outcomes (1)

• Percentage of exploitable films

  Ratio between the number of exploitable films and the number of films arriving at the telemedicine platform.

  Day 1 to day 7

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients followed in pneumology for asthma or COPD who have: * a prescription for long-term inhaled therapeutics * also a home health provider (either for long-term oxygen or for a CPAP, NIV ...)

You may qualify if:

• Patient followed in Pneumology for asthma or COPD with a prescription for long-term inhaled therapies AND a home health provider (who monitors either home oxygen and / or respiratory equipment)
• The patient must have a means of telephone communication in order to be able to be contacted by a provider, an H2AD permanence or a doctor
• Patient having given his agreement after having been informed in writing of the purpose and the data collected during this study
• Age ≥ 18 years
• Beneficiary of a social security scheme

You may not qualify if:

• Refusal of the patient
• Patient not understanding French
• Absence of home health provider
• Absence of means of telephone communication

Sponsors & Collaborators

• Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche: lead

Study Sites (1)

ANTADIR

Paris, 75006, France

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive; Asthma

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Bronchial Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 4, 2018
• First Posted: January 10, 2018
• Study Start: December 1, 2017
• Primary Completion: September 1, 2019
• Study Completion: November 1, 2019
• Last Updated: March 29, 2023

Record last verified: 2023-03

Locations

FR (1)